Tsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan.
Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
BMC Psychiatry. 2022 May 4;22(1):316. doi: 10.1186/s12888-022-03964-6.
The population-based National Health Insurance database was adopted to investigate the prevalence, correlates, and disease patterns of sedative-hypnotic use in elderly persons in Taiwan.
The National Health Research Institutes provided a database of 1,000,000 random subjects in the National Health Insurance program. We adopted this sample of subjects who were older than 65 years from 1997 to 2005 and examined the proportions of psychiatric and nonpsychiatric disorders with regard to sedative-hypnotic use.
The 1-year prevalence of sedative-hypnotic use in elderly individuals increased from 1.7% in 1997 to 5.5% in 2005. The 1-year prevalence rates of benzodiazepine (BZD) and non-BZD hypnotics were 3.2 and 3.1%, respectively, in 2005. The overall hypnotic use was highest in ≥85-year-olds, males, those with lower amounts of insurance or higher Charlson Comorbidity Index scores and those living in eastern Taiwan. Both BZD and non-BZD hypnotic use were most commonly used in nonpsychiatric disorders instead of psychiatric disorders. Among the psychiatric disorders, the disorders that accounted for higher BZD and non-BZD hypnotic use were senile and presenile organic psychotic conditions (3.4 and 3.4%, respectively). Higher BZD and non-BZD use was for diseases of the respiratory system (30.4 and 17.8%, respectively), the circulatory system (20.4 and 22.4%, respectively), and neoplasms (12.6 and 13.8%, respectively).
The prevalence rates of both BZD and non-BZD sedative-hypnotic use increased from 1997 to 2005 in the elderly. The risk factors for sedative-hypnotic use were aging, male sex, lower insurance amount, and higher Charlson Comorbidity Index scores. Most BZD and non-BZD sedative-hypnotic users were persons with nonpsychiatric disorders.
本研究采用基于人群的全民健康保险数据库,旨在调查台湾地区老年人镇静催眠药物使用的流行率、相关因素和疾病模式。
国家健康研究院提供了 1997 年至 2005 年国家健康保险计划中 100 万随机抽样对象的数据库。我们采用了这一年龄组大于 65 岁的样本,并检查了镇静催眠药物使用与精神和非精神疾病的比例。
1997 年至 2005 年,老年人中镇静催眠药物的 1 年使用率从 1.7%上升到 5.5%。2005 年苯二氮䓬(BZD)和非 BZD 催眠药的 1 年使用率分别为 3.2%和 3.1%。≥85 岁、男性、保险金额较低或 Charlson 合并症指数评分较高以及居住在台湾东部的老年人催眠药物总使用率最高。BZD 和非 BZD 催眠药的使用最常见于非精神疾病,而不是精神疾病。在精神疾病中,导致 BZD 和非 BZD 催眠药使用率较高的是老年和老年前期器质性精神病性障碍(分别为 3.4%和 3.4%)。BZD 和非 BZD 的使用更高的是呼吸系统疾病(分别为 30.4%和 17.8%)、循环系统疾病(分别为 20.4%和 22.4%)和肿瘤(分别为 12.6%和 13.8%)。
1997 年至 2005 年,老年人中 BZD 和非 BZD 镇静催眠药物的使用率均有所上升。镇静催眠药物使用的危险因素包括年龄增长、男性、保险金额较低和 Charlson 合并症指数评分较高。大多数 BZD 和非 BZD 镇静催眠药物使用者是非精神疾病患者。